Stough D, Stenn K, Haber R, Parsley WM, Vogel JE, Whiting DA, et al. Psychological effect, pathophysiology, and management of androgenetic alopecia in men. Mayo Clin Proc. 2005;80(10):1316–22.

Article  PubMed  Google Scholar 

Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol. 1977;97(3):247–54.

Article  CAS  PubMed  Google Scholar 

Cash TF. The psychology of hair loss and its implications for patient care. Clin Dermatol. 2001 Mar-Apr;19(2):161–6.

Sinclair R. Male pattern androgenetic alopecia. BMJ. 1998;317(7162):865–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Alfonso M, Richter-Appelt H, Tosti A, Viera MS, García M. The psychosocial impact of hair loss among men: a multinational European study. Curr Med Res Opin. 2005;21(11):1829–36.

Article  PubMed  Google Scholar 

Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, et al. Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol. 2012;24(3):311–8.

Article  PubMed  PubMed Central  Google Scholar 

Bingham KD, Shaw DA. The metabolism of testosterone by human male scalp skin. J Endocrinol. 1973;57(1):111–21.

Article  CAS  PubMed  Google Scholar 

Yun S-I, Lee S-K, Goh E-A, Kwon OS, Choi W, Kim J, et al. Weekly treatment with SAMiRNA targeting the androgen receptor ameliorates androgenetic alopecia. Sci Rep. 2022;12(1):1607.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, et al. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther. 2020;33(3):e13379.

Article  CAS  PubMed  Google Scholar 

Erdemir F, Harbin A, Hellstrom WJ. 5-alpha reductase inhibitors and erectile dysfunction: the connection. J Sex Med. 2008;5(12):2917–24.

Article  PubMed  Google Scholar 

Mysore V, Shashikumar BM. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):128–34.

Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc. 2003;8(1):20–3.

Article  CAS  PubMed  Google Scholar 

Zito PM, Bristas KG, Syed K. Finasteride. StatPearls Publishing; 2022.

Google Scholar 

Kim JH, Na J, Bak DH, Lee BC, Lee E, Choi MJ, et al. Development of finasteride polymer microspheres for systemic application in androgenic alopecia. Int J Mol Med. 2019;43(6):2409–19.

CAS  PubMed  PubMed Central  Google Scholar 

Hosking AM, Juhasz M, Atanaskova MN. Complementary and Alternative Treatments for Alopecia: A Comprehensive Review. Skin Appendage Disord. 2019;5(2):72–89.

Article  PubMed  Google Scholar 

Brissos S, Veguilla MR, Taylor D, Balanza-Martinez V. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zolezzi M, Abouelhassan R, Eltorki Y, Haddad PM, Noorizadeh M. Long-Acting Injectable Antipsychotics: A Systematic Review of Their Non-Systemic Adverse Effect Profile. Neuropsychiatr Dis Treat. 2021;17:1917–26.

Article  PubMed  PubMed Central  Google Scholar 

Tuntland T, Ethell B, Kosaka T, Blasco F, Zang RX, Jain M, et al. Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research. Front Pharmacol. 2014;5:174.

Article  PubMed  PubMed Central  Google Scholar 

McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111–26.

Article  CAS  PubMed  Google Scholar 

Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol. 2003;30(12):2563–71.

CAS  PubMed  Google Scholar 

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48(1):35–45.

Article  CAS  PubMed  Google Scholar 

Bossie CA, Alphs LD, Correll CU. Long-acting injectable versus daily oral antipsychotic treatment trials in schizophrenia: pragmatic versus explanatory study designs. International Clinical Psychopharmacology. 2015;30(5).

Kane JM, Kishimoto T, Correll CU. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S37–41.

Poloni N, Ielmini M, Caselli I, Lucca G, Gasparini A, Gasparini A, et al. Oral Antipsychotic Versus Long-Acting Injections Antipsychotic in Schizophrenia Spectrum Disorder: a Mirror Analysis in a Real-World Clinical Setting. Psychopharmacol Bull. 2019;49(2):17–27.

PubMed  PubMed Central  Google Scholar 

Hughes DA. Estimation of the impact of noncompliance on pharmacokinetics: an analysis of the influence of dosing regimens. Br J Clin Phrmacol. 2008;65(6):871–8.

Article  CAS  Google Scholar 

Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry. 2003;64(16):18–23.

PubMed  Google Scholar 

Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrology Dialysis Transplantation. 2007;22(suppl_4):iv2-iv9.

Li Z, Radin A, Li M, Hamilton JD, Kajiwara M, Davis JD, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of dupilumab in healthy adult subjects. Clin Pharmacol drug Dev. 2020;9(6):742–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Carlin JR, Höglund P, Eriksson L, Christofalo P, Gregoire SL, Taylor AM, et al. Disposition and pharmacokinetics of [14C] finasteride after oral administration in humans. Drug Metab Dispos. 1992;20(2):148–55.

CAS  PubMed  Google Scholar 

Ohtawa M, Morikawa H, Shimazaki J. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of N-(2-methyl-2-propyl)-3-oxo-4-aza-5α-androst-1-ene-17β-carboxamide, a new type of specific competitive inhibitor of testosterone 5α-reductase, in volunteers. Eur J Drug Metab Pharmacokinet. 1991;16:15–21.

Article  CAS  PubMed  Google Scholar 

Le T, Aguilar B, Mangal JL, Acharya AP. Oral drug delivery for immunoengineering. Bioeng Transl Med. 2022;7(1): e10243.

Article  PubMed  Google Scholar 

Buckley DA, Du Vivier AW. The therapeutic use of topical contact sensitizers in benign dermatoses. Br J Dermatol. 2001;145(3):385–405.

Article  CAS  PubMed  Google Scholar 

McClellan KJ, Markham A. Finasteride: a review of its use in male pattern hair loss. Drugs. 1999;57(1):111–26.

Article  CAS  PubMed  Google Scholar 

Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16–27.

Article  CAS  PubMed  Google Scholar 

Arrowsmith J. Trial watch: Phase II failures: 2008–2010. Nat Rev Drug Discov. 2011;10(5):328–9.

Article  CAS  PubMed  Google Scholar 

Lim HS. Evolving role of modeling and simulation in drug development. Transl Clin Pharmacol. 2019;27(1):19–23.

Article  PubMed  PubMed Central  Google Scholar 

Day RO, Williams KM. Open-label extension studies. Drug Saf. 2007;30(2):93–105.

Article  PubMed  Google Scholar 

Kahan BC, Cro S, Doré CJ, Bratton DJ, Rehal S, Maskell NA, et al. Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials. Trials. 2014;15(1):456.

Article  PubMed  PubMed Central  Google Scholar 

Trone JC, Ollier E, Chapelle C, Bertoletti L, Cucherat M, Mismetti P, et al. Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis. Anna Oncol. 2018;29(4):803–11.

Article  CAS  Google Scholar 

Paton C, Craig TKJ, McConnell B, Barnes TRE. Side-effect monitoring of continuing LAI antipsychotic medication in UK adult mental health services. Ther Adv Psychopharmacol. 2021;11:2045125321991278.

Article  PubMed  PubMed Central  Google Scholar 

Haddad P, Fleischhacker WW. 47 Adverse effects and antipsychotic long-acting injections. In: Haddad P, Lambert T, Lauriello J, editors. Antipsychotic long-acting injections. Oxford: Oxford University Press; 2010.

Chapter  Google Scholar 

Irwig MS, Kolukula S. Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med. 2011;8(6):1747–53.

Article  PubMed  Google Scholar 

Mysore V. Finasteride and sexual side effects. Indian Dermatol Online J. 2012;3(1):62–5.

Article